Welcome to Joshua Entrop - Red Door Analytics

We are excited to introduce our newest team member, Dr Joshua Entrop, who is joining us as a Biostatistician and Associate Director of Business Development. With Joshua’s addition to our team, we are placing more emphasis on the strategic development of Red Door Analytics to ensure the continued success and growth of our company in the coming years.

Three questions to Joshua

What did you work on before you joined Red Door Analytics?

Right after I finished my Master’s degree in 2020, I began as a PhD student at the Cancer Epidemiology Group, part of the Clinical Epidemiology Division at Karolinska Institutet in Stockholm. During my PhD studies, we combined registry data from Sweden, Denmark, and Norway to study childbearing in lymphoma survivors. I really enjoyed exploring and learning about the various data sources across Scandinavia and trying to integrate them to improve our scientific projects. As a spin-off from these projects, I also developed a new model for estimating the mean number of events when competing events exist.

In addition to my PhD studies, I also worked as a statistician within the same research group, where I helped seting up a large registry linkage, called LymphomaBaSe, around the Swedish lymphoma registry and provided statistical expertise to various internal and external research projects.

Why did you decide to join Red Door Analytics?

I deeply enjoy doing research. For me, as a statistician, this means answering research questions in the best possible way using advanced, up-to-date statistical methods. I felt that this is exactly what Red Door Analytics is all about. Working as a Biostatistician allows me to assist other researchers and clients with their research without the need to develop my own medical hypotheses or research questions.

What are you most excited about in your new role at Red Door Analytics?

In my role as a Biostatistician, I am looking forward to expanding my knowledge by working on projects in medical areas that I haven’t yet explored. However, what I am probably most excited about is contributing to the strategic development of Red Door Analytics in my role as Associate Director of Business Development.

List of selected publications

Development and Application of Modern Statistical Methods for Studies of Childbearing Among Lymphoma Survivors, PhD thesis
Reproduction patterns among non-Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway: A population-based matched cohort study, British Journal of Haematology
Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway-A population-based matched cohort study, International Journal of Cancer
Parametric Estimation of the Mean Number of Events in the Presence of Competing Risks, Biometrical Journal

News

New Publication in Journal of the American College of Cardiology

This brief report asks a fundamental question for anyone using administrative claims data in cardiovascular research: how accurately do Medicare billing codes capture surgical procedural details? Conduit counts from Medicare CPT codes, ICD-10 codes, and the STS Adult Cardiac Surgery Database (STS-ACSD) were each validated against surgeon-dictated operative notes as the reference standard – with […]

New Publication in Journal of the American College of Cardiology

This large national analysis of over 1.2 million Medicare beneficiaries tackled a long-standing question in cardiac surgery: does multiarterial grafting (MAG) during coronary artery bypass grafting truly improve survival over single arterial grafting (SAG)? Using flexible parametric survival models with time-dependent effects and regression standardisation to derive standardised survival probabilities, two analytical approaches were compared […]

Our Contributions to EHA 2026 in Stockholm

We’re excited to announce that our team contributed to six abstracts at this year’s EHA Congress, held right here in Stockholm. The contributions span both lymphoma and myeloma/MGUS research, including one oral presentation, and reflect our ongoing work in haematological malignancies. A big thank you to the entire team involved in these projects. Lymphoma […]

New Publication in Blood Cancer Journal

This large, prospective population-based study from Iceland investigated whether SARS-CoV-2 vaccination affects M protein trajectories in over 1,800 individuals with MGUS or smoldering multiple myeloma (SMM). Using linear mixed-effects models with patient-specific trajectories, flexible spline-based age modelling, and standardised marginal comparisons, the study found that annual increases in M protein levels were small and similar […]

New Publication in Statistics in Medicine

In this recent article, the authors present a biologically motivated natural history model of tumour growth and metastatic progression that directly incorporates the effects of hormonal therapy. By embedding treatment within the mathematical framework, the model captures treatment duration, latent metastatic growth, and the seeding process in ways that traditional statistical methods cannot. The work […]

New Publication in European Urology Oncology

In our recent publication, we investigated the dynamic relationship between quality of life (QoL) and disease progression or death in metastatic hormone-sensitive prostate cancer (mHSPC), using data from two large phase III randomised trials—ARASENS and ARANOTE. By applying joint models that simultaneously analyse longitudinal QoL trajectories and time-to-event outcomes, the study shows that patients receiving […]

Our Contributions to EASL 2026 in Barcelona

We’re excited to announce that our team contributed to six abstracts at this year’s EASL Congress in Barcelona, reflecting our ongoing work in hepatology. A special thanks to Dr Rickard Strandberg for his contributions to these projects. List of Abstracts at EASL 2026 Potential of reflex testing with the CORE model triggered by liver enzyme abnormalities to […]

New Publication in BMC Medical Research Methodology

In our latest publication, we developed a new methodological approach to obtain fair comparisons of survival probabilities (and differences thereof) across study clusters such as hospitals, regions or other hierarchical units. The proposed approach combines posterior prediction of the random effects with regression standardisation to account for differences in the case-mix distribution between the clusters. […]

New Publication in Drug Discovery Today

Check out the latest position piece published in Drug Discovery Today on the use of open-source software in the pharmaceutical industry—a topic of growing importance as the sector undergoes a major transformation in how statistical analyses are conducted and validated. As part of his work at Red Door Analytics, Dr Alessandro Gasparini contributed to this publication […]

New Publication in the Journal of the American Heart Association

In our latest publication, we used Medicare administrative data to examine the relationship between neighbourhood deprivation and survival outcomes following coronary artery bypass grafting (CABG). The results showed that while patients from less deprived neighbourhoods consistently had better survival rates compared to those from highly deprived areas, this survival advantage varied significantly across racial and […]

New Publication in the European Heart Journal

In our latest publication we used Swedish register data to examine familial aggregation of congenital heart defects (CHD) across kinships and generations. The authors found clear dose-response patterns between CHD risk and the number of affected relatives. Recurrence patterns varied by kinship type and degree of genetic relatedness, with the strongest associations observed among mothers, […]

New Publication in The International Journal of Cancer

In our latest publication, we used Swedish register data to investigate how the timing of disease progression affects survival in patients with mantle cell lymphoma (MCL). MCL is an aggressive form of lymphoma characterized by frequent relapses, making it crucial to understand the long-term impact of disease progression on patient outcomes. The current study includes […]